Form 4: Werewolf Therapeutics' Chief Business Officer Acquires Stock Options

Steven H. Bloom, Chief Business Officer of Werewolf Therapeutics, Inc., reports the acquisition of stock options.

Summary

• Steven H. Bloom, the Chief Business Officer of Werewolf Therapeutics, Inc. (HOWL), filed a Form 4 on May 2, 2025, reporting a transaction.
• On May 1, 2025, Mr. Bloom acquired stock options to purchase 201,720 shares of common stock at an exercise price of $0.87.
• The options were granted as an inducement for Mr. Bloom's employment with the company and vest over a period of four years, with 25% vesting on April 16, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to an executive, which is a common practice.

Positives

• The granting of stock options to a key executive like the Chief Business Officer can align their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

The vesting schedule of the options suggests a commitment from the Chief Business Officer to remain with the company for at least four years.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Stakeholder Impact

• The granting of stock options can potentially benefit shareholders by aligning management's interests with the company's long-term success.

Key Dates

Keywords

Form 4, stock options, insider trading, Werewolf Therapeutics, HOWL, Steven H. Bloom, Chief Business Officer, equity compensation